VRTX News Alert Vertex Pharmaceuticals Inc (VRTX) 110.86 12/16/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Vertex Pharmaceuticals Inc (VRTX) 110.86 $VRTX

Where Are They Now? A Look Back at the Best & Worst Biotech CEOs
at The Street - Tue Dec 16, 10:20AM CST
One biotech CEO won accolades in 2010 only to be razzed for poor performance in 2011.
VRTX: 110.86 (-2.02), MYGN: 33.02 (-0.41), DNDN: 0.13 (-0.02), CTIC: 2.21 (-0.01), REGN: 396.13 (-4.88), CELG: 110.09 (-1.79)

Stock Market News for December 16, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Tue Dec 16, 9:10AM CST
Markets finished a choppy session in the negative territory on Monday as yet another slide in oil prices dented investor sentiment
KMI: 38.07 (-0.21), BIIB: 325.13 (-10.67), VRTX: 110.86 (-2.02), COG: 30.22 (+0.42), AMGN: 159.44 (-0.16), MRO: 25.31 (+0.51), CVX: 101.70 (+0.84), REGN: 396.13 (-4.88), PETM: 81.02 (+0.05)

Shares of VRTX Up 22.4% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Mon Dec 15, 9:18AM CST
SmarTrend identified an Uptrend for Vertex Pharmaceuticals (NASDAQ:VRTX) on September 18th, 2014 at $95.87. In approximately 3 months, Vertex Pharmaceuticals has returned 22.41% as of today's recent price of $117.35.
VRTX: 110.86 (-2.02)

David Altshuler, M.D., Ph.D., Joins Vertex as Executive Vice President of Global Research and Chief Scientific Officer
Business Wire - Mon Dec 15, 8:01AM CST
Vertex Pharmaceuticals Incorporated today announced that David Altshuler, M.D., Ph.D., will join the company as Executive Vice President, Global Research and Chief Scientific Officer. Dr. Altshuler was one of the four founding members of the Broad Institute of Harvard University and the Massachusetts Institute of Technology, where he has served as Deputy Director and Chief Academic Officer since 2009. Dr. Altshuler is also currently a Professor of Genetics and Medicine at Harvard Medical School and an Adjunct Professor of Biology at the Massachusetts Institute of Technology and has been an attending physician at the Massachusetts General Hospital. His scientific research has been focused on the discovery of new pathophysiological processes underlying the risk of developing type 2 diabetes to identify and validate new drug targets. At Vertex, Dr. Altshuler will lead the company's research efforts aimed at discovering new medicines for the treatment of serious diseases, overseeing activities across the company's five research sites in the United States, Canada and Europe.
VRTX: 110.86 (-2.02)

Top Healthcare Stocks for 2014
Todd Campbell, The Motley Fool - Motley Fool - Sun Dec 14, 10:03AM CST
Source: Flickr user  Tax Credits . This past year has been a great one for healthcare investors -- the S&P healthcare index ETF offered double the return of the S&P 500. Biotechnology stocks dominated the list of the 10 top-performing...
MNK: 91.05 (-1.12), MDVN: 102.50 (-1.58), CNC: 101.19 (-1.75), AGN: 205.75 (-3.26), VRTX: 110.86 (-2.02), ALNY: 92.08 (-1.87), EW: 125.44 (-1.57), ILMN: 175.18 (-3.13), SNY: 45.38 (+0.98), REGN: 396.13 (-4.88), PBYI: 195.44 (+0.11)

Watch for Vertex Pharmaceuticals to Potentially Pullback After Gaining 3.05% Yesterday
Comtex SmarTrend(R) - Thu Dec 11, 4:02PM CST
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $117.85 to a high of $122.26. Yesterday, the shares gained 3.1%, which took the trading range above the 3-day high of $121.65 on volume of 1.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
VRTX: 110.86 (-2.02)

After Yesterday's Rally of 3.05% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Thu Dec 11, 4:01PM CST
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $117.85 to a high of $122.26. Yesterday, the shares gained 3.1%, which took the trading range above the 3-day high of $121.65 on volume of 1.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
VRTX: 110.86 (-2.02)

Why Gilead Sciences and AbbVie Care About This Tiny Company
Todd Campbell, The Motley Fool - Motley Fool - Thu Dec 11, 9:18AM CST
Source: Gilead Sciences via Google Maps. Investors are focusing on AbbVie 's hepatitis C drug and its potential impact on Gilead Sciences ' hepatitis C market share if it wins FDA approval later this month. However, they might also want to keep...
VRTX: 110.86 (-2.02), GILD: 100.46 (-2.70), ACHN: 12.92 (+0.20), ABBV: 65.25 (-0.37)

Biotech Stock Roundup: Cubist to be Acquired by Merck, Bluebird Shoots Up on ASH Data - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Dec 10, 2:10PM CST
Yet another acquisition agreement was announced even as the biotech sector was busy with showcasing data at ASH.
BLUE: 85.87 (-0.33), BIIB: 325.13 (-10.67), VRTX: 110.86 (-2.02), CBST: 96.73 (+0.42), INCY: 71.62 (-0.52), AMGN: 159.44 (-0.16), ARRY: 4.59 (-0.04)

MassMutual Announces the Election of Three Members to its Board of Directors
PR Newswire - Wed Dec 10, 11:00AM CST
Massachusetts Mutual Life Insurance Company (MassMutual) announced today it has elected three new members to its Board of Directors: Isabella D. (Bella) Goren, former Chief Financial Officer of American Airlines, Inc. and AMR Corporation; Mark T. Bertolini, Chairman, Chief Executive Officer and President of Aetna Inc., and Jeffrey M. Leiden, M.D., Ph.D., Chairman, President and CEO of Vertex Pharmaceuticals Incorporated. With the three additions, MassMutual will have 15 Board of Director members.
VRTX: 110.86 (-2.02), AET: 85.64 (-1.03)

Stocks Are Dragged Lower as Oil Prices Plunge to 5-Year Low
at The Street - Mon Dec 08, 3:24PM CST
Oil prices were a sinking ship on Monday, capsizing energy stocks and almost everything else caught in their wake.
TSLA: 197.81 (-6.23), VRTX: 110.86 (-2.02), XOM: 86.41 (-0.49), COP: 63.22 (+1.53), SPWR: 23.71 (+0.45), CELG: 110.09 (-1.79), NFLX: 316.44 (-10.60), FSLR: 40.90 (-0.76), CBST: 96.73 (+0.42), GILD: 100.46 (-2.70), TOT: 49.42 (+0.68), MRK: 56.80 (-0.15), BP: 35.76 (+0.82), CVX: 101.70 (+0.84), REGN: 396.13 (-4.88), XLE: 74.01 (+0.65)

Stocks Recover From Session Lows Though Oil Prices Continue to Hurt
at The Street - Mon Dec 08, 2:30PM CST
Plunging crude oil prices and a selloff in energy stocks are weighing on benchmark indices again on Monday, limiting potential gains spurred by a rally among pharmaceuticals.
TSLA: 197.81 (-6.23), VRTX: 110.86 (-2.02), XOM: 86.41 (-0.49), COP: 63.22 (+1.53), SPWR: 23.71 (+0.45), INFY: 31.00 (+0.12), CELG: 110.09 (-1.79), NFLX: 316.44 (-10.60), FSLR: 40.90 (-0.76), RIG: 16.78 (+0.53), CBST: 96.73 (+0.42), GILD: 100.46 (-2.70), MRK: 56.80 (-0.15), EOG: 85.47 (+0.13), MCD: 88.72 (+0.26), CVX: 101.70 (+0.84), OXY: 74.41 (+1.25), REGN: 396.13 (-4.88), YUM: 69.02 (-1.61), XLE: 74.01 (+0.65)

Stocks Near Flatline as Rally in Pharmaceuticals Overshadows Energy Selloff
at The Street - Mon Dec 08, 10:04AM CST
Stocks trade flat as a rally in pharmaceuticals trumps a selloff in oil-related companies and plunging crude prices.
VRTX: 110.86 (-2.02), COP: 63.22 (+1.53), INFY: 31.00 (+0.12), CELG: 110.09 (-1.79), CBST: 96.73 (+0.42), EBAY: 55.94 (+0.50), RIG: 16.78 (+0.53), GILD: 100.46 (-2.70), MRK: 56.80 (-0.15), EOG: 85.47 (+0.13), MCD: 88.72 (+0.26), OXY: 74.41 (+1.25), REGN: 396.13 (-4.88), YUM: 69.02 (-1.61)

Time to Buy This Dip in Gilead Sciences, Inc. Stock?
George Budwell, The Motley Fool - Motley Fool - Mon Dec 08, 7:07AM CST
The past month hasn't been kind to shareholders of Gilead Sciences . After the stock reached an all-time high of $116.83 in November, shares have now fallen over 10% in roughly a three-week span. What's more, investors and hedge funds alike have...
JNJ: 102.76 (-1.20), VRTX: 110.86 (-2.02), GILD: 100.46 (-2.70), MRK: 56.80 (-0.15), ABBV: 65.25 (-0.37)

Vertex Pharmaceuticals Up 23.0% Since SmarTrend Uptrend Call (VRTX)
Comtex SmarTrend(R) - Fri Dec 05, 4:54PM CST
SmarTrend identified an Uptrend for Vertex Pharmaceuticals (NASDAQ:VRTX) on September 18th, 2014 at $95.87. In approximately 3 months, Vertex Pharmaceuticals has returned 23.03% as of today's recent price of $117.95.
VRTX: 110.86 (-2.02)

Biotech Stock Roundup: Avanir to be Acquired by Japanese Firm, Biogen Scores in Alzheimer's Study - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Dec 03, 9:51AM CST
Although it was a relatively uneventful week, mergers and acquisitions show no signs of slowing down in the biotech sector.
BIIB: 325.13 (-10.67), AVNR: 16.91 (-0.04), VRTX: 110.86 (-2.02), INCY: 71.62 (-0.52), ALXN: 177.73 (-5.48), PBYI: 195.44 (+0.11), REGN: 396.13 (-4.88)

Migraine - Pipeline Review, H2 2014
M2 - Wed Dec 03, 7:48AM CST
Research and Markets (http://www.researchandmarkets.com/research/xq8n9b/migraine) has announced the addition of the "Migraine - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Migraine, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Migraine and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Migraine - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Migraine pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Ache Laboratorios Farmaceuticos - Alder Biopharmaceuticals - Allergan - Amgen - Astellas Pharma - Avanir Pharmaceuticals - BioDelivery Sciences - Biofrontera - Bristol-Myers Squibb - D-Pharm - Eli Lilly and Company - Heptares Therapeutics - Impax Laboratories - IntelGenx - Istituto Italiano di Tecnologia - Medestea Research & Production - Merck & Co - Nektar Therapeutics - Northern Light Pharmaceuticals - Paladin Labs - Pfizer - Pozen - Proreo Pharma - Questcor Pharmaceuticals - Revance Therapeutics - TheraJect - Transcept Pharmaceuticals - Trigemina - Vertex Pharmaceuticals Incorporated - iCeutica For more information visit http://www.researchandmarkets.com/research/xq8n9b/migraine
VRTX: 110.86 (-2.02), AMGN: 159.44 (-0.16), LLY: 69.26 (-0.41), BMY: 57.69 (-0.86), NKTR: 14.47 (-0.03), AGN: 205.75 (-3.26), IPXL: 29.09 (-1.55), ALDR: 24.79 (-0.77), QCOR: 93.60 (+1.52), MRK: 56.80 (-0.15), TSPT: 1.70 (-0.04), RVNC: 16.46 (+0.12), POZN: 9.03 (+0.10)

‘Fast Money’ Recap: Can Stocks Still Rally if Oil Prices Rebound?
at The Street - Wed Dec 03, 4:00AM CST
The trading panel discussed energy stocks, biotechs and Taser.
BIIB: 325.13 (-10.67), ABT: 43.40 (-0.06), VRTX: 110.86 (-2.02), F: 14.09 (-0.19), BMRN: 86.06 (-1.17), RRGB: 70.51 (-1.08), XOP: 43.88 (+1.13), BBRY: 9.51 (+0.08), IBB: 293.67 (-3.99), CP: 182.52 (+4.71), TASR: 22.85 (-0.02), XLE: 74.01 (+0.65), CELG: 110.09 (-1.79)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Travel Disruptions Reveal the Value of Human Support

Updated Category News Views 21

Air travel’s ugly little secret surfaced again during the recent ground stop: a reservation is easy, but rescuing a trip is labor-intensive, fast-moving work. Internova Travel Group says its people across Travel Leaders Network, Global Travel Collection and ALTOUR moved quickly as cancellations piled up and travelers were left staring at busted itineraries. That is not...

Continue Reading
SDG&E's 21-Year Reliability Run Has Real Investor Weight

Updated Category News Views 66

Seventy minutes without power in a year is the sort of number most people ignore until their refrigerator quits humming. For San Diego Gas & Electric customers, though, it is a meaningful operating result: roughly 70 minutes annually from unplanned outages, on average, over the past decade, alongside fewer than one sustained outage per customer each year. SDG&E has also...

Continue Reading
Corner Bakery Bets on Holiday Catering Convenience

Updated Category News Views 150

A $50 carrot on a $350 catering tab tells you exactly where Corner Bakery sees the holiday battlefield: not in one lonely cookie sale, but in the larger group order that can make a restaurant’s day. The chain is pushing holiday catering through November and December, pairing that discount with bakery trays, meals for groups and a promise to handle delivery setup. It is...

Continue Reading
Saturn and Tileward Put GPU Memory Back to Work Now

Updated Category News Views 7

GPU memory is the tollbooth nobody notices until the whole AI highway backs up. Saturn Cloud’s new partnership with Tileward goes straight at that constraint: use compressed open-model weights, free memory on hardware already installed, and turn that reclaimed capacity into more tokens that an operator can actually sell. It is not glamorous. It may be one of the more...

Continue Reading
SOCi's MCP Push Makes Context the Product Moat Bigger

Updated Category News Views 135

Software agents without decent business context are just eager interns with access to the keyboard. SOCi’s November 19, 2026 announcement gets at that unglamorous truth: the company has made its Model Context Protocol server generally available and says its context layer now connects with more than 140 integrations. It is not a flashy new chatbot stunt. It is a bid to...

Continue Reading
MTI Adds Aviation Veterans as Acorn Builds MRO Plan

Updated Category News Views 95

Two old hands entering a boardroom can matter more than another glossy growth slogan, especially in aircraft maintenance, where a delayed part can ground an airplane and turn a customer relationship sour in a hurry. MTI Aviation has added Tony DiSimone Sr. and Aviv Tzur to its board, a move announced November 20, 2026, after Acorn Capital Management took a majority...

Continue Reading
Why Dent Repair Estimates Need More Than a Simple Ruler

Updated Category News Views 38

A dent can look harmless in a parking-lot glare and still turn into a stubborn repair job once somebody examines the metal properly. That is the useful, unglamorous point Jason Phelps of Magic Dent makes in a HelloNation article: visible diameter is not a verdict. Anybody shopping for vehicle repairs, managing fleet costs, or watching the collision-service ecosystem ought...

Continue Reading
Siteimprove Turns Accessibility Checks Into Agent Spend

Updated Category News Views 180

Accessibility work has usually been the thing teams promise to fix after the launch party is over. Siteimprove is trying to shove that discipline directly into the AI-agent workflow, announcing on November 19, 2026 that its Siteimprove.ai Accessibility Agent is available through Agentic Commerce on AWS Marketplace. The practical hook is simple enough: an AI agent can...

Continue Reading
Pennsylvania Housing Finds Its October Holding Pattern

Updated Category News Views 65

Pennsylvania's October housing numbers have the uneasy stillness of a pond before somebody throws a rock. The statewide median sales price sat at $315,000, exactly where it was in September, while sales barely cleared 10,400 and available listings kept inching higher. Nothing in that mix screams boom or bust. Frankly, that is the point: a market can look calm on the...

Continue Reading
TOP-REAL Tests Digital Monitoring in HER2 Cancer Care

Updated Category News Views 110

A cancer treatment can be extraordinarily potent and still get derailed by what happens on an ordinary Tuesday at home. That unglamorous gap between clinic visits is the whole point of TOP-REAL, a phase II academic study presented at ESMO AI & Digital Oncology 2026. Solti and its European partners are testing whether closer digital follow-up can catch trouble early enough...

Continue Reading

Top 5 Most Recently Viewed Articles

Pharvaris Shares Promising Data on Deucrictibant Efficacy

Updated Category News Views 186

Pharvaris Highlights Clinical Progress in HAE Treatment At the recent AAAAI/WAO Joint Congress, Pharvaris presented compelling long-term clinical data supporting the use of deucrictibant, a novel oral treatment for hereditary angioedema (HAE). This data underscores the drug's potential to not only prevent but also effectively address HAE attacks, offering hope to those...

Continue Reading
First Horizon Opens New Banking Center Celebrating Local Pride

Updated Category News Views 349

First Horizon Unveils New Banking Center with Appalachian Spirit First Horizon Bank (NYSE: FHN) proudly celebrated the grand opening of its newly refreshed banking center. The location pays tribute to the vibrant Appalachian State community, showcasing a striking theme that reflects its strong ties with Appalachian State University and its athletics. This celebration...

Continue Reading
Understanding Namodenoson's Role in Liver Cancer and Beyond

Updated Category News Views 243

Innovative Research on Namodenoson’s Impact in Liver Cancer Therapy Namodenoson, developed by Can-Fite BioPharma Ltd., is making waves in the medical community as a promising candidate for liver cancer treatment. Unlike traditional chemotherapy, which often harms healthy cells, Namodenoson is lauded for its protective qualities towards normal body systems. Published...

Continue Reading
Geotab Enhances Public Sector Solutions with Technological Advancements

Updated Category News Views 147

Geotab Enhances Public Sector Solutions with Technological Advancements Geotab Inc., a leader in connected vehicle solutions and asset management, has taken a major step forward in serving the public sector by expanding its cooperative purchasing contracts with Sourcewell and Canoe Procurement Group. This expansion introduces four cutting-edge solutions aimed at enhancing...

Continue Reading
Dun & Bradstreet Earns TRUSTe Certification for Responsible AI

Updated Category News Views 351

Dun & Bradstreet Achieves TRUSTe Responsible AI Certification Dun & Bradstreet (NYSE:DNB), recognized globally as a leading provider of business decisioning data and analytics, has been awarded the TRUSTe Responsible AI Certification. This certification signifies the company’s commitment to ethical and responsible governance in the realm of artificial intelligence (AI)....

Continue Reading